TF and cancer: In comparison, van Doormaal et al did not report significant differences in fibrin generation time between cancer patients and healthy individuals [17], and Thaler et al reported that MVs from patients with metastatic pancreatic cancer had a limited effect on time to fibrin clot formation despite a significantly higher MV-associated TF-activity as measured with a chromogenic, factor Xa-based assay [42].